Tuesday, June 3, 2014

Zenosense, Inc. (ZENO) Pursues MRSA Detection Device to Combat Cell Pervasiveness

Healthcare technology company, Zenosense, with an eye on developing and bringing to market a device for use in hospitals to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug,” is flagging numerous published media articles of late regarding MRSA and Super-Bugs.

ScienceDaily, reporting on an article in The New England Journal of Medicine about a new highly-resistant MRSA bacterium, stated University of Texas Health Science Center’s international research team has identified a new superbug which has caused a bloodstream infection in a patient in Brazil. This case is the first reported bloodstream infection caused by a highly vancomycin-resistant MRSA bacteria. Vancomycin [vang-kuh-mahy-sin] is considered the least expensive antibiotic used for the treatment of invasive MRSA.

In one CBS News story the media outlet cites a study showing MRSA is residing in people’s homes as well as healthcare settings. The story states that according to the lead researcher at Columbia University Medical Center, MRSA is now endemic in households. Published April 21, 2014 in Proceedings of the National Academy of Sciences, the findings are based on a study of 161 New York City residents who contracted MRSA between 2009 and 2011. It was determined that people’s residences were housing the MRSA strain USA300, which is the leading cause of community MRSA infections in the U.S.

U.S. News has reported on Electronic Cigarette vapor appearing to increase the virulence of MRSA as well. An abstract from a study conducted by the University of California-San Diego and the VA San Diego Healthcare System claims that MRSA cells exposed to the e-cigarette vapor in the lungs of mice with pneumonia were three times more likely to survive than MRSA cells not exposed to the vapor. The lead researcher attributed the greater virulence to a change in pH, causing the MRSA bacteria to become defensive and less vulnerable to attack.

Zenosense is a detection device development company based in Valencia, Spain. Its mission is develop, market, and sell an effective MRSA detector through its licensed-in technology, for sale to healthcare providers for use in clinical settings.

For more information on the company, visit www.zenosense.net

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: